FindTrial
Sign In

Efficacy and safety of polyethylene glycol loxenatide in combination with basal insulin in patients with type 2 diabetes mellitus: a retrospective cohort study

Efficacy and safety of polyethylene glycol loxenatide in combination with basal insulin in patients with type 2 diabetes mellitus: a retrospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086699
Enrollment
Unknown
Registered
2024-07-09
Start date
2024-07-15
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Control group: basal insulin treatment:none
Treatment group: basal insulin combined with losenatide treatment group:none

Sponsors

The Third XiangYa Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: (1) Patients with type 2 diabetes mellitus, =18 years old; (2) Patients with basal insulin therapy failing to meet control goals, 7.0% = HbA1c = 11.0%;

Exclusion criteria

Exclusion criteria: (1)Patients with type 1 diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Glycosylated hemoglobin;—

Secondary

MeasureTime frame
Weight;Blood pressure;Basal insulin dosage;Body Mass Index;Total cholesterol;High-density lipoprotein;Low-density lipoprotein;triglyceride;Fasting blood glucose;2-hour postporandial blood glucose;—

Countries

China

Contacts

Public ContactJin ping

The Third XiangYa Hospital of Central South University

ping.jin06@csu.edu.cn+86 136 3749 1977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026